Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00654238 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT00654238: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT00654238 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00654238, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
The goal of this study is to determine the activity of sorafenib in patients with advanced (metastatic or recurrent) thyroid cancer.
Interventions
- DRUG sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2006-02 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00654238
The ClinicalTrials.gov registry entry for NCT00654238 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sorafenib is the first listed.
NCT00654238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00654238 about?
NCT00654238 is a clinical study titled "Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer". The goal of this study is to determine the activity of sorafenib in patients with advanced (metastatic or recurrent) thyroid cancer.
What is the current status of trial NCT00654238?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2006-02. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00654238?
The interventions under investigation include: sorafenib (DRUG).
Who is sponsoring clinical trial NCT00654238?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.